Login / Signup

Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.

Yaning YangGuangjian YangWeihua LiXuezhi HaoShuyang ZhangXin AiSi-Yu LeiHai-Yan XuYan Wang
Published in: Thoracic cancer (2023)
In this study, pyrotinib plus antiangiogenic agents demonstrated promising efficacy and were tolerable in HER2-altered NSCLC patients.
Keyphrases
  • advanced non small cell lung cancer
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease